Prognostic and proliferative evaluation of ameloblastoma based on radiographic boundary

Abstract

Ameloblastomas are tumors that typically form in the lower jaw and leave patients and doctors with difficult choices. Although benign, ameloblastomas can grow aggressively. Clinicians must therefore choose between a conservative excision—and risk recurrence—or radical jaw surgery likely to reduce a patient’s quality of life. Long-jiang Li and colleagues at China’s Sichuan University have found that X-ray imaging can offer useful guidance. On reviewing 178 ameloblastoma cases, they determined that growths with poorly defined edges were more than twice as likely to recur following conservative surgery relative to ameloblastomas with clear boundaries. Cells in the former group of tumors also expressed higher levels of a genetic marker associated with cellular proliferation, further supporting the use of radical surgery to address such growths.

Keywords

ameloblastoma / Ki-67 / radiography / prognosis

References

[1] Laughlin EH. Metastasizing ameloblastoma. Cancer, 1989, 64(3): 776-780.

[2] Reichart PA, Philipsen HP, Sonner S. Ameloblastoma: biological profile of 3677 cases. Eur J Cancer, 1995, 31B(2): 86-99.

[3] Gardner DG. A pathologist's approach to the treatment of ameloblastoma. J Oral Maxillofac Surg, 1984, 42(3): 161-166.

[4] O'Donnell Evaluation of focal bone lesions: basic principles and clinical scenarios. Imaging, 2003, 15(4): 298-323.

[5] Lodwick GS, Wilson AJ, Farrell C. Determining growth rates of focal lesions of bone from radiographs. Radiology, 1980, 134(3): 577-583.

[6] Ueno S, Mushimoto K, Shirasu R. Prognostic evaluation of ameloblastoma based on histologic and radiographic typing. J Oral Maxillofac Surg, 1989, 47(1): 11-15.

[7] Meer S, Galpin JS, Altini M. Proliferating cell nuclear antigen and Ki67 immunoreactivity in ameloblastomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2003, 95(2): 213-221.

[8] Gardner DG, Heikinheimo K, Shear M. Ameloblastomas. World Health Organization Classification of Tumors. Pathology & Genetics of Head and Neck Tumours., 2005 Lyon 296-300.

[9] Takahashi K, Miyauchi K, Sato K. Treatment of ameloblastoma in children. Br J Oral Maxillofac Surg, 1998, 36(6): 453-456.

[10] Sammartino G, Zarrelli C, Urciuolo V. Effectiveness of a new decisional algorithm in managing mandibular ameloblastomas: a 10-years experience. Br J Oral Maxillofac Surg, 2007, 45(4): 306-310.

[11] Hong J, Yun PY, Chung IH. Long-term follow up on recurrence of 305 ameloblastoma cases. Int J Oral Maxillofac Surg, 2007, 36(4): 283-288.

[12] Muller H, Slootweg PJ. The ameloblastoma, the controversial approach to therapy. J Maxillofac Surg, 1985, 13(2): 79-84.

[13] Rapidis AD, Andressakis DD, Stavrianos SD. Ameloblastomas of the jaws: clinico-pathological review of 11 patients. Eur J Surg Oncol, 2004, 30(9): 998-1002.

[14] Gardner DG, Pecak AM. The treatment of ameloblastoma based on pathologic and anatomic principles. Cancer, 1980, 46(11): 2514-2519.

[15] Sehdev MK, Huvos AG, Strong EW. Proceedings: ameloblastoma of maxilla and mandible. Cancer, 1974, 33(2): 324-333.

[16] Kramer IR. Ameloblastoma: a clinicopathological appraisal. Br J Oral Surg, 1963, 1: 13-28.

[17] Sandra F, Mitsuyasu T, Nakamura N. Immunohistochemical evaluation of PCNA and Ki-67 in ameloblastoma. Oral Oncol, 2001, 37(2): 193-198.

[18] Han B, Li L, Wang H. Expression of Ki-67 antigen in ameloblastoma and its clinical significance. Hua Xi Kou Qiang Yi Xue Za Zhi, 2003, 21(2): 153-154.